May 01, 2013 at 11:33 AM EDT
Analyst Moves: BIIB, X, PFE
This morning, Goldman Sachs downgraded shares of Biogen (BIIB) from buy to neutral citing valuation. The stock has reached the firm's $215 price target, leaving less upside for investors.
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here